Login to Your Account

Clinic Roundup

Wednesday, January 16, 2013
• Navidea Biopharmaceuticals Inc., of Dublin, Ohio, said it completed a study testing radiopharmaceutical NAV4694 as a biomarker for visual detection and quantification of cerebral beta-amyloid in diagnosing Alzheimer's disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription